This article first appeared on GuruFocus.

Cytek Biosciences Inc (NASDAQ:CTKB) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $51.49 million, and the earnings are expected to come in at -$0.05 per share. The full year 2025's revenue is expected to be $196.25 million and the earnings are expected to be -$0.20 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 2 Warning Sign with CTKB.

Is CTKB fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Cytek Biosciences Inc (NASDAQ:CTKB) have declined from $197.97 million to $196.25 million for the full year 2025 and declined from $213.51 million to $210.48 million for 2026 over the past 90 days. Earnings estimates for Cytek Biosciences Inc (NASDAQ:CTKB) have increased from -$0.22 per share to -$0.20 per share for the full year 2025 and declined from -$0.15 per share to -$0.18 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Cytek Biosciences Inc's (NASDAQ:CTKB) actual revenue was $45.60 million, which missed analysts' revenue expectations of $46.34 million by -1.60%. Cytek Biosciences Inc's (NASDAQ:CTKB) actual earnings were -$0.04 per share, which beat analysts' earnings expectations of -$0.07 per share by 42.86%. After releasing the results, Cytek Biosciences Inc (NASDAQ:CTKB) was up by 5.66% in one day.

Based on the one-year price targets offered by 4 analysts, the average target price for Cytek Biosciences Inc (NASDAQ:CTKB) is $5.13 with a high estimate of $8.00 and a low estimate of $4.00. The average target implies an upside of 30.08% from the current price of $3.94.

Based on GuruFocus estimates, the estimated GF Value for Cytek Biosciences Inc (NASDAQ:CTKB) in one year is $7.53, suggesting an upside of 91.12% from the current price of $3.94.

Based on the consensus recommendation from 5 brokerage firms, Cytek Biosciences Inc's (NASDAQ:CTKB) average brokerage recommendation is currently 2.4, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.